Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [2] Core Views - The company is a leading domestic gene sequencer, with accelerated progress in both domestic and international markets. The dual drivers of domestic and overseas business are expected to enhance the company's market share [3][4] - The gene sequencing market is rapidly expanding, with a projected compound annual growth rate (CAGR) of 16.8% for the global gene sequencer and reagent market, expected to reach USD 20.2 billion by 2032 [4][48] - The company leverages its core DNBSEQ technology to build a comprehensive product pipeline, meeting diverse needs in research and clinical applications, with high accuracy and lower costs compared to global leader Illumina [4][5] Company Overview - The company has established itself as a domestic leader in gene sequencing instruments, continuously innovating and upgrading its product offerings, including the upcoming StandardMPS 2.0 sequencing reagent, which aims to lead the industry into the Q40 era of sequencing quality [4][18] - The company has a well-structured product matrix covering low, medium, and high throughput sequencing, with a focus on automation and AI integration to enhance operational efficiency and sequencing precision [4][21] Financial Performance and Forecast - The company is expected to achieve revenues of CNY 36.06 billion, CNY 42.81 billion, and CNY 49.32 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 19.7%, 18.7%, and 15.2% [5][6] - The projected net profit for the company is expected to turn positive by 2025, with estimates of CNY 0.07 billion, CNY 1.50 billion, and CNY 2.94 billion for the years 2025, 2026, and 2027, respectively [5][6] Industry Overview - The gene sequencing industry is experiencing rapid growth, driven by the expansion of downstream applications in clinical, research, and personal health management sectors. The global gene sequencing market is projected to grow from USD 15.54 billion in 2023 to USD 62.48 billion by 2030, with a CAGR of 22.2% [48][49] - The domestic gene sequencing market is expected to reach CNY 374 billion by 2024, with a projected CAGR of 26.5% from 2024 to 2030, supported by national policies and funding [62][63]

Core Insights - Illumina reported strong second quarter results for fiscal 2025, exceeding analyst expectations for both non-GAAP EPS and GAAP revenue, with non-GAAP EPS at $1.19 and GAAP revenue at $1.06 billion, despite a 3% decline from the previous year [1][5][11] - The company raised its full-year guidance, expecting non-GAAP EPS in the range of $4.45–$4.55 and non-GAAP operating margin at approximately 22%–22.5%, driven by better performance in clinical markets and strong adoption of NovaSeq X consumables [1][11][12] Financial Performance - Non-GAAP EPS reached $1.19, surpassing the consensus estimate of $1.01, marking a year-over-year increase of 9.2% [2] - GAAP revenue was $1.06 billion, slightly above the estimate of $1.05 billion, but down 3% from Q2 2024 [2][5] - Non-GAAP operating margin improved to 23.8%, up 1.6 percentage points year-over-year, reflecting effective cost control measures [2][6] - Net income (non-GAAP) was $187 million, a 7.5% increase from $174 million in the previous year [2] - Free cash flow was $204 million, down from $213 million year-over-year, indicating strong cash conversion despite a slight decline [2][10] Business Overview - Illumina specializes in DNA sequencing equipment, software, and supplies, serving clinical laboratories, research centers, and healthcare providers [3] - The company’s product portfolio includes high-throughput sequencers like NovaSeq X and lower-throughput options such as MiSeq i100, along with consumables and software solutions [3] Innovation and Market Strategy - Continuous investment in R&D is crucial for Illumina to develop advanced, cost-effective sequencing technologies [4] - The company aims to expand its presence in clinical markets while facing challenges in research funding [4] - Key success factors include successful commercialization of new products, regulatory compliance, international expansion (excluding China), and partnerships in emerging fields like multi-omics and AI [4] Operational Developments - The clinical market experienced mid-single-digit growth, which helped offset declines in research revenues, expected to drop by approximately 15% for the remainder of the year [7][12] - The company launched new products and upgrades, including TruSight Oncology 500 v2 and PromoterAI software, enhancing its product offerings [8][9] - Service and other revenue decreased by 20.5% due to the absence of one-off partnership revenue from the previous year [9] Future Outlook - Management anticipates a smaller decline in total company constant currency revenue, now expecting a range of 0.5% to 2.5% [11] - The improved outlook is primarily based on cost control and margin improvement rather than organic revenue growth, with continued challenges in the research segment and low revenue contribution from China [12]

Group 1 - The core strategy of the company is to consolidate its advantages in disposable protective products and rehabilitation equipment, with no current plans to invest in high-tech medical industries such as brain-computer interfaces or gene sequencing [1] - The company will focus on upgrading its core business technology and market expansion, and will fulfill its information disclosure obligations if there are any new business plans in the future [1]

来源：金融界 金融界8月1日消息，有投资者在互动平台向英科医疗提问：请问公司在保证主业行业地位的前提下，能 否适当投资开发脑机接口或基因测序等高科技医疗产业，实现一体两翼的发展战略。 公司回答表示：尊敬的投资者您好，公司当前战略核心是巩固一次性防护用品及康复器械的主业优势， 暂无布局脑机接口或基因测序等领域的计划。未来将聚焦主业技术升级与市场拓展，若有新业务规划， 会及时履行信息披露义务。感谢您的关注！ ...

Market Overview - The A-share market experienced a collective decline, with the Shanghai Composite Index falling by 1.18% to 3573 points, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1][2] - The total trading volume for the day reached 1.96 trillion yuan, an increase of 909 billion yuan compared to the previous trading day, with nearly 4300 stocks declining across the market [1] Sector Performance - The steel sector saw significant declines, with Baogang Co. dropping nearly 8% and coal stocks also experiencing widespread losses, such as Antai Group falling nearly 7% [2][14][15] - The aquaculture sector weakened, led by Zhongshui Fisheries, while lithium mining stocks fluctuated downwards, with companies like Shengxin Lithium Energy and CATL dropping nearly 5% [3] - Other sectors with notable declines included titanium dioxide, photovoltaic equipment, shipbuilding, and small metals [4] - Conversely, the liquid cooling concept rose against the trend, with stocks like Cambridge Technology and Chunz中科技 hitting the daily limit [5] Notable Stock Movements - The assisted reproduction sector surged as 31 provinces included assisted reproductive technology in medical insurance, leading to stocks like Anke Bio and Hancheng Group hitting the daily limit [6] - The composite fluid sector was active, with Nord Shares reaching the daily limit, while gene sequencing and AI concepts also saw significant gains [7] - Specific stocks in the AI hardware sector experienced substantial increases, with Sihuan New Materials and Fangsheng Shares both hitting the daily limit [8][9] - The innovative drug sector was vibrant, with stocks like Nanxin Pharmaceutical and Anke Bio also reaching the daily limit [12] Future Outlook - CITIC Securities suggests that it remains a good time to balance the Hong Kong and A-share allocation, recommending an increase in holdings of the Hang Seng Technology Index [17] - The firm also advises focusing on opportunities in the Sci-Tech 50, Sci-Tech chips, and Sci-Tech 100 for potential rebounds [17] - The recommendation includes rotating investments in sectors such as non-ferrous metals, communications, innovative drugs, military industry, and gaming, while also considering thematic investments in anti-involution stocks [17]

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index falling by 1.18% to 3573 points, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1][2] - The total trading volume for the day reached 1.96 trillion yuan, an increase of 90.9 billion yuan compared to the previous trading day, with nearly 4300 stocks declining across the market [1] Index Performance - Shanghai Composite Index: 3573.21, down 42.51 points (-1.18%) [2] - Shenzhen Component Index: 11009.77, down 193.26 points (-1.73%) [2] - ChiNext Index: 2328.31, down 39.37 points (-1.66%) [2] - Other indices such as the CSI 300 and CSI 500 also experienced declines of 1.82% and 1.40% respectively [2] Sector Performance - The steel sector saw significant declines, with Baogang Co. (600010) dropping nearly 8% [3] - Coal stocks also fell, with Antai Group declining nearly 7% [3] - The aquaculture sector weakened, led by Zhongshui Fishery (000798) [3] - Lithium mining concepts experienced fluctuations, with companies like Shengxin Lithium Energy and CATL (300750) dropping nearly 5% [3] - Other sectors such as titanium dioxide, photovoltaic equipment, shipbuilding, and small metals also reported notable declines [3] Notable Gainers - The liquid cooling concept saw gains, with companies like Cambridge Technology, Chunz中科技 (603516), and Ice Wheel Environment (000811) hitting the daily limit [3] - The assisted reproductive technology sector surged after being included in medical insurance, with companies like Anke Biotechnology (300009) and Hanshang Group (600774) also reaching the daily limit [3] - The composite fluid sector was active, with Nord Shares (600110) hitting the daily limit [3] - Other sectors such as gene sequencing, AI, and state-owned cloud concepts showed positive performance [3]

Core Viewpoint - The "Shenzhen-made" T1+ gene sequencer has successfully assisted the disease control system in sequencing and tracing the Chikungunya virus from four samples, achieving a sequencing coverage of over 99.9% [1] Group 1 - The T1+ gene sequencer is utilized to analyze Chikungunya virus samples, demonstrating high accuracy in sequencing [1] - Among the sequenced samples, two cases were identified as the East/Central/South African (ECSA) strain, while the other two were classified as the Asian strain [1]

Group 1 - The military equipment restructuring concept has declined by 4.64%, ranking among the top declines in the concept sector, with companies like Changcheng Military Industry, Huachuang Technology, and Zhongguang Optical leading the declines [1] - The military equipment restructuring concept experienced a net outflow of 1.041 billion yuan in main funds today, with six stocks seeing net outflows, and five stocks having outflows exceeding 30 million yuan [2] - The stock with the highest net outflow is Changcheng Military Industry, which saw a net outflow of 791 million yuan, followed by Chang'an Automobile, Huachuang Technology, and Hunan Tianyan with net outflows of 111 million yuan, 56.65 million yuan, and 49.12 million yuan respectively [2] Group 2 - The top decliners in the military equipment restructuring concept include Changcheng Military Industry with a decline of 7.86%, Huachuang Technology with a decline of 6.58%, and Zhongguang Optical with a decline of 6.08% [2] - The trading volume for Changcheng Military Industry was 15.52%, while the trading volume for Huachuang Technology was 3.27% [2] - The only stock in the military equipment restructuring concept that saw a positive net fund flow was Jianshe Industrial, with a net inflow of 33.09 million yuan [2]

Core Viewpoint - The gene sequencing sector has shown a modest increase of 0.44%, ranking fifth among concept sectors, with notable performances from stocks like Nanjing Xinbai and Zhaoyan New Drug [1][2]. Market Performance - The gene sequencing concept saw 29 stocks rise, with Nanjing Xinbai hitting the daily limit up, and other top gainers including Heyuan Biological and Qianyuan Pharmaceutical, which rose by 8.61%, 6.96%, and 6.43% respectively [1]. - Conversely, stocks like Puni Testing, Zhongyuan Co., and Betta Pharmaceuticals experienced declines of 3.73%, 2.71%, and 2.46% respectively [1]. Capital Flow - The gene sequencing sector attracted a net inflow of 122 million yuan, with 34 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - Zhaoyan New Drug led the sector with a net inflow of 203 million yuan, followed by Nanjing Xinbai and Qianyuan Pharmaceutical with net inflows of 111 million yuan and 64.63 million yuan respectively [2]. Capital Inflow Ratios - Nanjing Xinbai, Zhaoyan New Drug, and Heyuan Biological had the highest net inflow ratios at 43.57%, 12.72%, and 10.88% respectively [3].

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]